The Length of Hospital Stay of Patients with Venous Thromboembolism: A Cross-Sectional Study from Jordan
Abstract
:1. Introduction
2. Materials and Methods
2.1. Subjects and Data Collection
2.2. Statistical Analysis
3. Results
3.1. Characteristics of the VTE Patients
3.2. Predictors of Hospital Length of Stay (LOS)
4. Discussion
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Singh, S.; Kapoor, S.; Singh, B.; Tandon, R.; Singla, S.; Singla, T.; Bansal, V.; Singh, G.; Goyal, A.; Chhabra, S.T. Real world data on clinical profile, management and outcomes of venous thromboembolism from a tertiary care centre in India. Indian Heart J. 2021, 73, 336–341. [Google Scholar] [CrossRef] [PubMed]
- Yamashita, Y.; Morimoto, T.; Kimura, T. Venous thromboembolism: Recent advancement and future perspective. J. Cardiol. 2022, 79, 79–89. [Google Scholar] [CrossRef] [PubMed]
- Jimenez, S.; Ruiz-Artacho, P.; Merlo, M.; Suero, C.; Antolin, A.; Casal, J.R.; Sanchez, M.; Ortega-Duarte, A.; Genis, M.; Piñera, P. Risk profile, management, and outcomes of patients with venous thromboembolism attended in Spanish emergency departments: The ESPHERIA registry. Medicine 2017, 96, e8796. [Google Scholar] [CrossRef]
- LaMori, J.C.; Shoheiber, O.; Mody, S.H.; Bookhart, B.K. Inpatient Resource Use and Cost Burden of Deep Vein Thrombosis and Pulmonary Embolism in the United States. Clin. Ther. 2015, 37, 62–70. [Google Scholar] [CrossRef] [PubMed]
- Awolesi, D.; Naidoo, M.; Cassimjee, M.H. The profile and frequency of known risk factors or comorbidities for deep vein thrombosis in an urban district hospital in KwaZulu-Natal. S. Afr. J. HIV Med. 2016, 17, 1–5. [Google Scholar] [CrossRef]
- Badreldin, H. Hospital length of stay in patients initiated on direct oral anticoagulants versus warfarin for venous thromboembolism: A real-world single-center study. J. Thromb. Thrombolysis 2018, 46, 16–21. [Google Scholar] [CrossRef]
- Basto, A.N.; Fewel, N.P.; Vo, K.; Stock, E.M.; Ta, M. Initiation of direct oral anticoagulants versus warfarin for venous thromboembolism: Impact on time to hospital discharge. J. Thromb. Thrombolysis 2018, 45, 51–55. [Google Scholar] [CrossRef]
- Konstantinides, S.V.; Meyer, G.; Becattini, C.; Bueno, H.; Geersing, G.-J.; Harjola, V.-P.; Huisman, M.V.; Humbert, M.; Jennings, C.S.; Jiménez, D. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS) The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). Eur. Heart J. 2020, 41, 543–603. [Google Scholar]
- Organisation for Economic Co-operation and Development (OECD). Length of Hospital Stay (Indicator), 2022 ed.; OECD: Paris, France, 2022. [Google Scholar] [CrossRef]
- Buttigieg, S.C.; Abela, L.; Pace, A. Variables affecting hospital length of stay: A scoping review. J. Health Organ. Manag. 2018, 32, 463–493. [Google Scholar] [CrossRef]
- Toh, H.J.; Lim, Z.Y.; Yap, P.; Tang, T. Factors associated with prolonged length of stay in older patients. Singap. Med. J. 2017, 58, 134–138. [Google Scholar] [CrossRef] [Green Version]
- StataCorp, L. Stata data analysis and statistical Software. Spec. Ed. Release 2007, 10, 733. [Google Scholar]
- Whellan, D.J.; Zhao, X.; Hernandez, A.F.; Liang, L.; Peterson, E.D.; Bhatt, D.L.; Heidenreich, P.A.; Schwamm, L.H.; Fonarow, G.C. Predictors of Hospital Length of Stay in Heart Failure: Findings from Get With the Guidelines. J. Card. Fail. 2011, 17, 649–656. [Google Scholar] [CrossRef] [PubMed]
- Boupapanh, K.C.; Boupapanh, K.; Infosino, M.; Zhang, Y.; Shank, J. Evaluation of Comorbidities and Biomarkers to Predict Hospital Length-of-Stay and Mortality in VTE Patients. South. Med. J. 2022, 115, 63–64. [Google Scholar]
- Goldhaber, S.Z.; Ageno, W.; Casella, I.B.; Chee, K.H.; Schellong, S.; Singer, D.E.; Desch, M.; Reilly, P.A.; Donado, E.; Tang, W.; et al. Profile of Patients Diagnosed With Acute Venous Thromboembolism in Routine Clinical Practice: The RE-COVERY DVT/PE™ Study. Am. J. Med. 2020, 133, 936–945. [Google Scholar] [CrossRef] [PubMed]
- Zhang, G.; Xu, X.; Su, W.; Xu, Q. Smoking and risk of venous thromboembolism: A systematic review. Southeast Asian J. Trop. Med. Public Health 2014, 45, 736–745. [Google Scholar] [PubMed]
- Chang, S.-L.; Huang, Y.-L.; Lee, M.-C.; Hu, S.; Hsiao, Y.-C.; Chang, S.-W.; Chang, C.J.; Chen, P.-C. Association of Varicose Veins With Incident Venous Thromboembolism and Peripheral Artery Disease. JAMA 2018, 319, 807–817. [Google Scholar] [CrossRef] [Green Version]
- Anderson, M.R.; Shashaty, M.G.S. Impact of Obesity in Critical Illness. Chest 2021, 160, 2135–2145. [Google Scholar] [CrossRef]
- Rosito, G.A.; D’Agostino, R.B.; Massaro, J.; Lipinska, I.; Mittleman, M.A.; Sutherland, P.; Wilson, P.W.; Levy, D.; Muller, J.E.; Tofler, G.H. Association between obesity and a prothrombotic state: The Framingham Offspring Study. Thromb. Haemost. 2004, 91, 683–689. [Google Scholar] [CrossRef]
- Willenberg, T.; Schumacher, A.; Amann-Vesti, B.; Jacomella, V.; Thalhammer, C.; Diehm, N.; Baumgartner, I.; Husmann, M. Impact of obesity on venous hemodynamics of the lower limbs. J. Vasc. Surg. 2010, 52, 664–668. [Google Scholar] [CrossRef] [Green Version]
- ClinicalTrails.gov. Direct Oral Anticoagulants (DOACs) Versus LMWH +/− Warfarin for VTE in Cancer (CANVAS). ClinicalTrails.gov: 2023. Available online: https://clinicaltrials.gov/ct2/show/NCT02744092?term=Pulmonary+embolism&cond=DOACs&draw=2&rank=3 (accessed on 7 March 2023).
- Planquette, B.; Bertoletti, L.; Charles-Nelson, A.; Laporte, S.; Grange, C.; Mahé, I.; Pernod, G.; Elias, A.; Couturaud, F.; Falvo, N.; et al. Rivaroxaban vs Dalteparin in Cancer-Associated Thromboembolism: A Randomized Trial. Chest 2022, 161, 781–790. [Google Scholar] [CrossRef]
- Saint, C.A.; Castelli, M.R.; Crannage, A.J.; Stacy, Z.A.; Hennessey, E.K. Comparison of hospital length of stay in patients treated with non–vitamin K oral anticoagulants or parenteral agents plus warfarin for venous thromboembolism. SAGE Open Med. 2017, 5, 1–5. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Porath, A.D.; Clodfelter, S.; Slaton, T.; Bookhart, B.K.; Kozma, C.M.; Rand, M.L.; Bloch, M.J. Policy Change for Deep Vein Thrombosis: Effects on Length of Stay and Hospitalization Costs of Moving From Warfarin to Direct Oral Anticoagulants. Clin. Ther. 2019, 41, 269–279. [Google Scholar] [CrossRef] [PubMed]
- Groetzinger, L.M.; Miller, T.J.; Rivosecchi, R.M.; Smith, R.E.; Gladwin, M.T.; Rivera-Lebron, B.N. Apixaban or Rivaroxaban Versus Warfarin for Treatment of Submassive Pulmonary Embolism After Catheter-Directed Thrombolysis. Clin. Appl. Thromb. Hemost. 2018, 24, 908–913. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Coleman, C.I.; Baugh, C.; Crivera, C.; Milentijevic, D.; Wang, S.-W.; Lu, L.; Nelson, W.W. Healthcare costs associated with rivaroxaban or warfarin use for the treatment of venous thromboembolism. J. Med. Econ. 2017, 20, 200–203. [Google Scholar] [CrossRef]
- Margolis, J.M.; Deitelzweig, S.; Kline, J.; Tran, O.; Smith, D.M.; Bookhart, B.; Crivera, C.; Schein, J. Shorter hospital stays and lower costs for rivaroxaban compared with warfarin for venous thrombosis admissions. J. Am. Heart Assoc. 2016, 5, e003788. [Google Scholar] [CrossRef]
- Barisonzo, R.; Wiedermann, W.; Unterhuber, M.; Wiedermann, C.J. Length of stay as risk factor for inappropriate hospital days: Interaction with patient age and co-morbidity. J. Eval. Clin. Pract. 2013, 19, 80–85. [Google Scholar] [CrossRef]
- Daghistani, T.A.; Elshawi, R.; Sakr, S.; Ahmed, A.M.; Al-Thwayee, A.; Al-Mallah, M.H. Predictors of in-hospital length of stay among cardiac patients: A machine learning approach. Int. J. Cardiol. 2019, 288, 140–147. [Google Scholar] [CrossRef]
- Martinez Licha, C.R.; McCurdy, C.M.; Maldonado, S.M.; Lee, L.S. Current Management of Acute Pulmonary Embolism. Ann. Thorac. Cardiovasc. Surg. 2020, 26, 65–71. [Google Scholar] [CrossRef] [Green Version]
- Khdour, M.R.; Jarab, A.S.; Adas, H.O.; Samaro, E.Z.; Mukattash, T.L.; Hallak, H.O. Identification of drug-related problems: A prospective study in two general hospitals. Curr. Clin. Pharmacol. 2012, 7, 276–281. [Google Scholar] [CrossRef]
Diagnostic Procedure | Diagnosis (n%) | ||
---|---|---|---|
DVT | PE | Both | |
Venography | 2 (0.7%) | 2 (7.1%) | 1 (5.9%) |
MRI | 3 (1.1%) | 1 (3.6%) | 0 (0.0%) |
Ultrasound | 224 (83.0%) | 15 (53.6%) | 10 (58.8%) |
Ultrasonography | 26 (9.6%) | 5 (17.9%) | 5 (29.4%) |
Chest XR | 76 (51.4%) | 18 (90.0%) | 10 (76.9%) |
D-Dimer test | 75 (27.7%) | 12 (42.9%) | 7 (41.2%) |
Characteristics | n (%) |
---|---|
Age | |
<40 | 80 (25.2%) |
40–49 | 74 (23.3%) |
50–69 | 112 (35.3%) |
≥70 | 51 (16.1%) |
Gender | |
Male | 166 (52.37%) |
Female | 151 (47.63%) |
Diagnosis | |
DVT | 271 (85.8%) |
PE | 28 (8.9%) |
Both | 17 (5.4%) |
Smoker | |
Yes | 179 (57.2%) |
No | 134 (42.8%) |
BMI | |
Underweight (<18.5) | 36 (11.4%) |
Healthy weight (18.5 to <25) | 71 (22.4%) |
Overweight/obese (≥25) | 210 (66.3%) |
Immobilization | |
Yes | 66 (21.1%) |
No | 247 (78.9%) |
Recurrent DVT/PE | |
Yes | 112 (35.33%) |
No | 204 (64.67%) |
Hypertension | |
Yes | 130 (59%) |
No | 187 (41%) |
Diabetes Mellitus | |
Yes | 87 (27.4%) |
No | 230 (72.6%) |
Cardiovascular Disease (MI, CHF and stroke) | |
Yes | 58 (18.3%) |
No | 259 (81.7%) |
Blood transfusion (<1 month) | |
Yes | 21 (6.62%) |
No | 296 (93.4%) |
Hormone Replacement Therapy or steroids | |
Yes | 23 (7.3%) |
No | 294 (92.7%) |
Vit D deficiency | |
Yes | 38 (12%) |
No | 279 (88%) |
Surgery/anesthesia > 45 min | |
Yes | 20 (6.3%) |
No | 297 (93.7%) |
Hypothyroidism | |
Yes | 19 (6%) |
No | 298 (94%) |
CKD | |
Yes | 22 (6.9%) |
No | 295 (93.1%) |
Hyperlipidemia | |
Yes | 19 (6%) |
No | 298 (94%) |
Hypercoagulable state | |
Yes | 14 (4.4%) |
No | 303 (95.6%) |
Lung Disease | |
Yes | 18 (5.7%) |
No | 299 (94.3%) |
Malignancy/Chemotherapy | |
Yes | 26 (8.2%) |
No | 291 (91.8%) |
Charlson Comorbidity Index (CCI) | |
CCI = 0 | 85 (26.8%) |
CCI = 1–2 | 167 (52.7%) |
CCI = 3–4 | 55 (17.4%) |
CCI ≥ 5 | 10 (3.2%) |
Warfarin + Enoxaparin | |
Yes | 128 (40.4%) |
No | 189 (59.6%) |
Warfarin + Tinzaparin | |
Yes | 84 (26.5%) |
No | 191 (73.5%) |
Warfarin + UFH | |
Yes | 11 (3.47%) |
No | 306 (96.5%) |
Number of DVT symptoms | |
0–1 | 39 (12.4%) |
2–3 | 114 (36.3%) |
4–5 | 161 (51.3%) |
Presence of visible varicose vein | |
Yes | 56 (17.67%) |
No | 261 (82.3%) |
Number of comorbidities | |
0–1 | 136 (42.9%) |
2–3 | 111 (35%) |
4–5 | 55 (17.4%) |
≥6 | 15 (4.73%) |
Polypharmacy | |
Yes | 80 (25.24%) |
No | 237 (74.76%) |
Variable | LOS: 1–3 Days n = 34 (11%) | LOS: 4–6 Days n = 135 (44%) | LOS: ≥7 Days n = 138 (45%) | p-Value | |
---|---|---|---|---|---|
Age | <40 | 13 (38.2%) | 23 (17%) | 42 (30.5%) | <0.001 |
40–49 | 12 (35.3%) | 27 (20%) | 33 (23.9%) | ||
50–69 | 9(26.5%) | 54 (40%) | 45 (32.6%) | ||
≥70 | 0 | 31 (23%) | 18 (13%) | ||
Hypertension | Yes | 7 (20.6%) | 55 (49.7%) | 64 (46.4%) | 0.019 |
No | 27 (79.4%) | 80 (59.3%) | 74 (53.6%) | ||
Diabetes Mellitus | Yes | 3 (8.8%) | 42 (31.1%) | 39 (28.3%) | 0.023 |
No | 31 (91.2%) | 93 (68.9%) | 99 (71.7%) | ||
Cardiovascular Diseases | Yes | 3 (8.8%) | 34 (25.2%) | 20 (14.5%) | 0.028 |
No | 31 (91.2%) | 101 (74.8%) | 118 (85.5%) | ||
Warfarin + Tinzaparin | Yes | 8 (23.5%) | 46 (34.1%) | 28 (20.3%) | 0.033 |
No | 26 (76.5%) | 89 (65.9%) | 110 (79.7%) | ||
Visible Varicose Vein | Yes | 4 (11.8%) | 34 (25.2%) | 17 (12.3%) | 0.014 |
No | 30 (88.2%) | 101 (74.8%) | 121 (87.7%) | ||
Hypercoagulable state | Yes | 3 (8.8%) | 8 (5.9%) | 2 (1.5%) | 0.03 |
No | 31 (91.2%) | 127 (94.1%) | 136 (98.5%) |
Variables | Adjusted Odds Ratio (AOR) | Standard Error (SE) | p-Value | 95% Confidence Interval | |
---|---|---|---|---|---|
Age | <40 | Ref | |||
40–49 | 0.64 | 0.22 | 0.179 | 0.32–1.23 | |
50–69 | 0.57 | 0.18 | 0.075 | 0.30–1.1 | |
≥70 | 0.48 | 0.19 | 0.067 | 0.22–1.1 | |
Hypertension | No | Ref | |||
Yes | 2.1 | 0.60 | 0.011 | 1.18–3.70 | |
Diabetes Mellitus | No | Ref | |||
Yes | 1.07 | 0.31 | 0.81 | 0.6–1.9 | |
Cardiovascular Diseases | No | Ref | |||
Yes | 0.69 | 0.20 | 0.207 | 0.38–1.23 | |
Warfarin + Tinzaparin | No | Ref | |||
Yes | 0.59 | 0.15 | 0.037 | 0.36–0.97 | |
Visible Varicose Vein | No | Ref | |||
Yes | 0.82 | 0.23 | 0.498 | 0.47–1.44 | |
Hypercoagulable state | No | Ref | |||
Yes | 0.30 | 0.17 | 0.029 | 0.11–0.89 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Amawi, H.; Arabyat, R.M.; Al-Azzam, S.; AlZu’bi, T.; U’wais, H.T.; Hammad, A.M.; Amawi, R.; Nusair, M.B. The Length of Hospital Stay of Patients with Venous Thromboembolism: A Cross-Sectional Study from Jordan. Medicina 2023, 59, 727. https://doi.org/10.3390/medicina59040727
Amawi H, Arabyat RM, Al-Azzam S, AlZu’bi T, U’wais HT, Hammad AM, Amawi R, Nusair MB. The Length of Hospital Stay of Patients with Venous Thromboembolism: A Cross-Sectional Study from Jordan. Medicina. 2023; 59(4):727. https://doi.org/10.3390/medicina59040727
Chicago/Turabian StyleAmawi, Haneen, Rasha M. Arabyat, Sayer Al-Azzam, Toqa AlZu’bi, Hamza Tayseer U’wais, Alaa M. Hammad, Ruba Amawi, and Mohammad B. Nusair. 2023. "The Length of Hospital Stay of Patients with Venous Thromboembolism: A Cross-Sectional Study from Jordan" Medicina 59, no. 4: 727. https://doi.org/10.3390/medicina59040727